This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Board meeting set for November 5 to approve Q2 2026 results
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.5 pts more than Nifty Microcap 250 and 1.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board will meet on 5 November 2026 to approve unaudited financials and a limited review report for the quarter ended 30 September 2026. The announcement does not provide revenue, profit, debt or cash flow figures.
This only confirms the meeting date. Shareholder reactions will depend on the results released after the meeting.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹25.33 Cr | ₹18.50 Cr | +36.9% |
| Operating profit | ₹5.43 Cr | ₹5.03 Cr | +8.0% |
| Profit after tax | ₹4.15 Cr | ₹4.64 Cr | −10.6% |
| EBITDA margin | 25.6% | 28.4% | −2.8 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.